On this page

Hydrocortisone Acetate Pramoxine Hcl

Prescription ANDA Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Hydrocortisone Acetate Pramoxine Hcl
Generic name
Hydrocortisone Acetate Pramoxine Hcl
Dosage form
Cream
Route
Topical
Marketing category
UNAPPROVED DRUG OTHER · UNAPPROVED
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
3
NDC product codes
17
Packages
23
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Hydrocortisone Acetate 1 g/100g 1291082 View
Hydrocortisone Acetate 2.5 g/100g 1291082 View
Pramoxine Hydrochloride 1 g/100g 1234532 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
40

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
085368
Application type
ANDA · Abbreviated New Drug Application
Approval date
January 7, 1977
Sponsor
LEGACY
Products on application
1
Submissions recorded
19
Products approved under application 085368.
Product Trade name Form Strength Ingredient Status TE Flags
085368-001 PRAMOSONE CREAM HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE Prescription —

Approval history

Source: Drugs@FDA
Most recent submissions on application 085368.
Type No. Action Status Date Review
Supplement 23 Manufacturing (CMC) Approved December 6, 2001 —
Supplement 22 Manufacturing (CMC) Approved September 21, 2001 —
Supplement 21 Manufacturing (CMC) Approved September 21, 2001 —
Supplement 20 Manufacturing (CMC) Approved February 5, 2001 —
Supplement 19 Manufacturing (CMC) Approved September 21, 2000 —
Supplement 18 Manufacturing (CMC) Approved August 11, 2000 —
Supplement 17 Manufacturing (CMC) Approved March 1, 1999 —
Supplement 16 Manufacturing (CMC) Approved August 20, 1992 —
Supplement 15 Labeling Approved June 3, 1992 —
Supplement 14 Manufacturing (CMC) Approved June 3, 1992 —
Supplement 13 Manufacturing (CMC) Approved June 3, 1992 —
Supplement 11 Labeling Approved June 3, 1992 —
Supplement 12 Manufacturing (CMC) Approved April 27, 1992 —
Supplement 9 Manufacturing (CMC) Approved April 27, 1992 —
Supplement 8 Labeling Approved April 27, 1992 —
Supplement 10 Manufacturing (CMC) Approved November 7, 1988 —
Supplement 7 Manufacturing (CMC) Approved December 21, 1984 —
Supplement 6 Manufacturing (CMC) Approved December 21, 1984 —
Original application 1 Approved January 7, 1977 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251024). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251024 HUMAN PRESCRIPTION DRUG · 20241227 HUMAN PRESCRIPTION DRUG · 20241226 HUMAN PRESCRIPTION DRUG · 20220531

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Topical corticosteroids are generally applied to the affected area as a thin film three to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria To report SUSPECTED ADVERSE REACTIONS, contact Saptalis Pharmaceuticals, LLC at 1-833-727-8254 or FDA at 1800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Hydrocortisone Acetate 2.5% and Pramoxine HCl 1% Cream is a topical preparation containing hydrocortisone acetate 2.5% w/w and pramoxine hydrochloride 1% w/w in a hydrophilic cream base containing stearic acid, cetyl alcohol, Aquaphor®, isopropyl palmitate, polyoxyl 40 stearate, propylene glycol, potassium sorbate, sorbic acid, triethanolamine lauryl sulfate, and purified water. Topical corticosteroids are anti-inflammatory and anti-pruritic agents. The structural formula, the chemical name, molecular formula and molecular weight for the active ingredients are presented below. hydrocortisone acetate Pregn-4-ene-3, 20-dione, 21-(acetyloxy)-11, 17-dihydroxy-, (11-beta)- C 23 H 32 O 6 ; mol. wt: 404.50 pramoxine hydrochloride 4-(3-(p-butoxyphenoxy)propyl)morpholine hydrochloride C 17 H 27 NO 3 .HCl; mol. wt: 329.87 Chemical Structure Chemical Structure

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS . )

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Hydrocortisone Acetate 2.5% and Pramoxine HCl 1% Cream is available as follows: NDC: 71335-2934-1: 57 g in a TUBE Store at 25oC (77oF); excursions permitted to 15-30oC (59-86oF) [see USP Controlled Room Temperature]. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504

Adverse event reports

Source: openFDA FAERS
73,232
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: HYDROCORTISONE ACETATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
63629-8669-1 63629-8669 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8669-1) / 28.35 g in 1 TUBE April 13, 2010
63629-8670-1 63629-8670 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8670-1) / 28.35 g in 1 TUBE July 20, 2021
63629-8671-1 63629-8671 Bryant Ranch Prepack 12 TUBE in 1 CARTON (63629-8671-1) / 4 g in 1 TUBE July 20, 2021
63629-8672-1 63629-8672 Bryant Ranch Prepack 30 TUBE in 1 CARTON (63629-8672-1) / 4 g in 1 TUBE July 20, 2021
63629-8673-1 63629-8673 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8673-1) / 28.4 g in 1 TUBE July 20, 2021
63629-8674-1 63629-8674 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8674-1) / 57 g in 1 TUBE March 29, 2011
71335-2932-1 71335-2932 Bryant Ranch Prepack 1 TUBE in 1 CARTON (71335-2932-1) / 28.35 g in 1 TUBE October 28, 2025
71335-2934-1 71335-2934 Bryant Ranch Prepack 1 TUBE in 1 CARTON (71335-2934-1) / 57 g in 1 TUBE October 24, 2025
71335-2939-1 71335-2939 Bryant Ranch Prepack 12 TUBE in 1 CARTON (71335-2939-1) / 4 g in 1 TUBE October 28, 2025
71335-2942-1 71335-2942 Bryant Ranch Prepack 30 TUBE in 1 CARTON (71335-2942-1) / 4 g in 1 TUBE October 28, 2025
72162-1394-2 72162-1394 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1394-2) / 57 g in 1 TUBE December 24, 2024
72162-1394-4 72162-1394 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1394-4) / 28.4 g in 1 TUBE December 24, 2024
72162-1399-3 72162-1399 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1399-3) / 28.35 g in 1 TUBE August 17, 2023
72162-1411-2 72162-1411 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1411-2) / 28.35 g in 1 TUBE December 24, 2024
72162-1411-3 72162-1411 Bryant Ranch Prepack 30 TUBE in 1 CARTON (72162-1411-3) / 4 g in 1 TUBE December 24, 2024
72162-1411-4 72162-1411 Bryant Ranch Prepack 12 TUBE in 1 CARTON (72162-1411-4) / 4 g in 1 TUBE December 24, 2024
45802-124-16 45802-124 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-124-16) / 57 g in 1 TUBE March 29, 2011
45802-124-64 45802-124 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-124-64) / 28.4 g in 1 TUBE March 29, 2017
45802-144-64 45802-144 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-144-64) / 28.35 g in 1 TUBE April 13, 2010
45802-472-53 45802-472 Padagis Israel Pharmaceuticals Ltd 12 TUBE in 1 CARTON (45802-472-53) / 4 g in 1 TUBE (45802-472-01) May 3, 2010
45802-472-64 45802-472 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-472-64) / 28.35 g in 1 TUBE April 13, 2010
45802-472-65 45802-472 Padagis Israel Pharmaceuticals Ltd 30 TUBE in 1 CARTON (45802-472-65) / 4 g in 1 TUBE (45802-472-01) May 3, 2010
52817-817-01 52817-817 TRUPHARMA, LLC 1 TUBE in 1 CARTON (52817-817-01) / 28.4 g in 1 TUBE November 19, 2020
63629-8669 63629-8669 Bryant Ranch Prepack — April 13, 2010
63629-8670 63629-8670 Bryant Ranch Prepack — September 27, 1996
63629-8671 63629-8671 Bryant Ranch Prepack — September 27, 1996
63629-8672 63629-8672 Bryant Ranch Prepack — September 27, 1996
63629-8673 63629-8673 Bryant Ranch Prepack — March 29, 2011
63629-8674 63629-8674 Bryant Ranch Prepack — March 29, 2011
71335-2932 71335-2932 Bryant Ranch Prepack — September 27, 1996
71335-2934 71335-2934 Bryant Ranch Prepack — March 29, 2011
71335-2939 71335-2939 Bryant Ranch Prepack — September 27, 1996
71335-2942 71335-2942 Bryant Ranch Prepack — September 27, 1996
72162-1394 72162-1394 Bryant Ranch Prepack — March 29, 2011
72162-1399 72162-1399 Bryant Ranch Prepack — April 13, 2010
72162-1411 72162-1411 Bryant Ranch Prepack — September 27, 1996
45802-124 45802-124 Padagis Israel Pharmaceuticals Ltd — March 29, 2011
45802-144 45802-144 Padagis Israel Pharmaceuticals Ltd — April 13, 2010
45802-472 45802-472 Padagis Israel Pharmaceuticals Ltd — September 27, 1996
52817-817 52817-817 TRUPHARMA, LLC — November 19, 2020

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 10 sections on this page.